Recombinant Human NBL1 protein (rFc Tag)(HPLC verified)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Human NBL1 protein (rFc Tag)(HPLC verified) (Eg2940)

Species

Human

Purity

>90 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg2940

---

Validation Data Gallery

• 

  Purity of Recombinant Human NBL1 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

• 

  The purity of Human NBL1 was greater than 90% as determined by SEC-HPLC.

---

Product Information

• Purity: >90 %, SDS-PAGE; >90 %, SEC-HPLC
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human NBL1 protein Ala17-Asp181 (Accession# P41271-1) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 4681
• Accession: P41271-1
• PredictedSize: 43.7 kDa
• SDS-PAGE: 45-55 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

NBL1 (neuroblastoma suppression of tumorigenicity 1), also named as DAN, is the founding member of the DAN subfamily. It was originally identified as a putative tumor suppressor gene in a transformed fibroblast rat model, whereby it was significantly down-regulated in v-src-transformed rat fibroblasts. The MW of this protein is 19 kDa, and this antibody specially recognises the 19 kDa protein.

References:

1. Tsai CH. et al.  (2023) Biomolecules. 13(11):1570. 
2. Ladenstein R. et al. (2018) Lancet Oncol. 19(12):1617-1629. 
3. Lu L. et al. (2022) Oncogenesis. 11(1):21. 
4. Du J. et al. (2023) Thorac Cancer. 14(30):3032-3041. 
5. Wang A. et al. (2022) Parasitol Res. 121(5):1369-1378.